Pregnancy in PAH Patients Focus of Recent Study

A recent systematic review titled “Pregnancy and pulmonary arterial hypertension: A clinical conundrum,” highlights that pulmonary arterial hypertension (PAH) is an absolute contraindication for pregnant women. Pulmonary arterial hypertension (PAH) is a rare condition that causes progressive increases in pulmonary arterial pressure and pulmonary…

Respira Brings on New CTO To Lead Development of PAH Drug Delivery System

Albuquerque-based Respira Therapeutics, Inc. is a biopharmaceutical company currently developing a dry powder inhaler drug delivery technology called AOS-DPI for RT234, a drug that is being designed to address pulmonary hypertension and other respiratory diseases such as IPF and COPD. In an effort to bolster the company’s commercialization efforts, they recently announced that Andy Clark has been appointed…

SteadyMed Raises $12.2M to Advance PAH Therapy

Specialty pharmaceutical company SteadyMed Ltd. recently raised $12.2 million in equity financing, co-led by subsidiaries of Federated Investors Inc. and Deerfield Management Company L.P., as well as existing shareholders from the company. The funding will be invested in SteadyMed’s therapeutic product candidates for the treatment of orphan diseases, including…

Right Ventricular Remodeling Might be Adaptative in Idiopathic Pulmonary Arterial Hypertension

Researchers at the School of Medicine at Sapienza University of Rome found that Concentric hypertrophy in the heart right ventricle might represent a favorable adaptive pattern to increased afterload in idiopathic pulmonary arterial hypertension. The study, entitled “Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus…

ERS Pulmonary Hypertension Research Still Open to Applicants

The ERS Pulmonary Hypertension Research Award will grant €40,000 to a pair of carefully selected scientists currently pursuing active research projects in the field of pulmonary hypertension, with regard to its pathophysiology, basic science, epidemiology, clinical practice, prevention, treatment, diagnosis or rehabilitation. The awards are reserved exclusively for candidates younger than 45 years old at the time…

Researchers Study PAH in Rheumatoid Arthritis Versus Idiopathic PAH

A new study out of Toronto, Canada has evaluated whether rheumatoid arthritis-associated pulmonary arterial hypertension (RA-PAH) is a more severe disease compared to idiopathic pulmonary arterial hypertension (IPAH). Published on January 13, 2015, the study is titled “Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared…


A Conversation With Rare Disease Advocates